Health and Healthcare
Taiwan Liposome Advances Its Hydroxychloroquine Inhalation Study
Published:
Taiwan Liposome Co. Ltd. (NASDAQ: TLC) made progress in the fight against COVID-19 on Wednesday when it enrolled its first subject for its coronavirus treatment. This treatment differs from others because it is administered via an inhaler and includes the controversial hydroxychloroquine as part of the treatment.
The company previously received the go-ahead for this study from regulatory bodies in both Australia and Taiwan. The approval comes following the acceptance of Taiwan Liposome’s investigational new drug (IND) application with the Taiwan Food and Drug Administration last week.
In terms of the specifics, the first subject has been enrolled in the Phase 1 clinical trial of TLC19 for the treatment or prophylaxis of COVID-19. Ultimately, this study will evaluate the safety, tolerability and pharmacokinetics of single ascending doses of inhaled TLC19 in 30 healthy volunteers.
Management has said that it is very much looking forward to launching TLC19’s Phase 1 trial with the support of experienced, high-quality partners in Taiwan, as well as in Australia, which has an efficient and globally recognized regulatory environment with the bonus of government incentives and benefits and is a great place to conduct clinical trials for time-sensitive projects like TLC19.
Excluding Wednesday’s move, Taiwan Liposome stock had underperformed the broad markets with a retreat of about 14% year to date. In the past 52 weeks, the share price was down closer to 8%.
Taiwan Liposome stock traded up about 5% to $4.81 on Wednesday, in a 52-week range of $2.48 to $12.65. The consensus price target is $12.75.
The Average American Is Losing Their Savings Every Day (Sponsor)
If you’re like many Americans and keep your money ‘safe’ in a checking or savings account, think again. The average yield on a savings account is a paltry .4% today, and inflation is much higher. Checking accounts are even worse.
Every day you don’t move to a high-yield savings account that beats inflation, you lose more and more value.
But there is good news. To win qualified customers, some accounts are paying 9-10x this national average. That’s an incredible way to keep your money safe, and get paid at the same time. Our top pick for high yield savings accounts includes other one time cash bonuses, and is FDIC insured.
Click here to see how much more you could be earning on your savings today. It takes just a few minutes and your money could be working for you.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
